Furthermore, in cultured lymphocytes from untreated MS patients, the A2A receptor agonist inhibited the release of TNF-α, IL-6, IL-1β, IFN-γ, and IL-17 following the incubation with phorbol myristate acetate. Here, IL17A is linked to myeloid sarcoma.